Association and regulation of protein factors of field effect in prostate tissues

Gabriel,Kristin  N.; Jones,Anna  C.; Nguyen,Julie   P.T.; Antillon,Kresta   S.; Janos,Sara   N.; Overton,Heidi   N.; Jenkins,Shannon   M.; Frisch,Emily   H.; Trujillo,Kristina   A.; Bisoffi,Marco

doi:10.3892/ijo.2016.3666

Association and regulation of protein factors of field effect in prostate tissues

Authors:
- Kristin N. Gabriel
- Anna C. Jones
- Julie P.T. Nguyen
- Kresta S. Antillon
- Sara N. Janos
- Heidi N. Overton
- Shannon M. Jenkins
- Emily H. Frisch
- Kristina A. Trujillo
- Marco Bisoffi
View Affiliations

Affiliations: Biochemistry and Molecular Biology, Schmid College of Science and Technology, Chapman University, Orange, CA, USA, Department of Biochemistry and Molecular Biology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
Published online on: August 22, 2016 https://doi.org/10.3892/ijo.2016.3666
Pages: 1541-1552

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Field effect or field cancerization denotes the presence of molecular aberrations in structurally intact cells residing in histologically normal tissues adjacent to solid tumors. Currently, the etiology of prostate field‑effect formation is unknown and there is a prominent lack of knowledge of the underlying cellular and molecular pathways. We have previously identified an upregulated expression of several protein factors representative of prostate field effect, i.e., early growth response-1 (EGR‑1), platelet-derived growth factor‑A (PDGF‑A), macrophage inhibitory cytokine‑1 (MIC‑1), and fatty acid synthase (FASN) in tissues at a distance of 1 cm from the visible margin of intracapsule prostate adenocarcinomas. We have hypothesized that the transcription factor EGR‑1 could be a key regulator of prostate field‑effect formation by controlling the expression of PDGF‑A, MIC‑1, and FASN. Taking advantage of our extensive quantitative immunofluorescence data specific for EGR‑1, PDGF‑A, MIC‑1, and FASN generated in disease‑free, tumor‑adjacent, and cancerous human prostate tissues, we chose comprehensive correlation as our major approach to test this hypothesis. Despite the static nature and sample heterogeneity of association studies, we show here that sophisticated data generation, such as by spectral image acquisition, linear unmixing, and digital quantitative imaging, can provide meaningful indications of molecular regulations in a physiologically relevant in situ environment. Our data suggest that EGR‑1 acts as a key regulator of prostate field effect through induction of pro‑proliferative (PDGF‑A and FASN), and suppression of pro‑apoptotic (MIC‑1) factors. These findings were corroborated by computational promoter analyses and cell transfection experiments in non‑cancerous prostate epithelial cells with ectopically induced and suppressed EGR‑1 expression. Among several clinical applications, a detailed knowledge of pathways of field effect may lead to the development of targeted intervention strategies preventing progression from pre-malignancy to cancer.

View Figures

View References

1	Epstein JI: Mimickers of prostatic intraepithelial neoplasia. Int J Surg Pathol. 18(Suppl): 142S–148S. 2010. View Article : Google Scholar : PubMed/NCBI
2	Montironi R, Mazzucchelli R, Algaba F and Lopez-Beltran A: Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance. J Clin Pathol. 53:655–665. 2000. View Article : Google Scholar : PubMed/NCBI
3	De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer. 7:256–269. 2007. View Article : Google Scholar : PubMed/NCBI
4	De Marzo AM, Marchi VL, Epstein JI and Nelson WG: Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol. 155:1985–1992. 1999. View Article : Google Scholar : PubMed/NCBI
5	Slaughter DP, Southwick HW and Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 6:963–968. 1953. View Article : Google Scholar : PubMed/NCBI
6	Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR and Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res. 63:1727–1730. 2003.PubMed/NCBI
7	Dakubo GD, Jakupciak JP, Birch-Machin MA and Parr RL: Clinical implications and utility of field cancerization. Cancer Cell Int. 7:22007. View Article : Google Scholar : PubMed/NCBI
8	Halin S, Hammarsten P, Adamo H, Wikström P and Bergh A: Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer. Expert Opin Med Diagn. 5:37–47. 2011. View Article : Google Scholar : PubMed/NCBI
9	Nonn L, Ananthanarayanan V and Gann PH: Evidence for field cancerization of the prostate. Prostate. 69:1470–1479. 2009. View Article : Google Scholar : PubMed/NCBI
10	Trujillo KA, Jones AC, Griffith JK and Bisoffi M: Markers of field cancerization: Proposed clinical applications in prostate biopsies. Prostate Cancer. 2012:3028942012. View Article : Google Scholar : PubMed/NCBI
11	Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK and Bisoffi M: Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol. 35:537–546. 2009.PubMed/NCBI
12	Jones AC, Antillon KS, Jenkins SM, Janos SN, Overton HN, Shoshan DS, Fischer EG, Trujillo KA and Bisoffi M: Prostate field cancerization: Deregulated expression of macrophage inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A (PDGF-A) in tumor adjacent tissue. PLoS One. 10:e01193142015. View Article : Google Scholar : PubMed/NCBI
13	Jones AC, Trujillo KA, Phillips GK, Fleet TM, Murton JK, Severns V, Shah SK, Davis MS, Smith AY, Griffith JK, et al: Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization. Prostate. 72:1159–1170. 2012. View Article : Google Scholar
14	Mora GR, Olivier KR, Cheville JC, Mitchell RF Jr, Lingle WL and Tindall DJ: The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate. Mol Cancer Res. 2:115–128. 2004.PubMed/NCBI
15	Pagel JI and Deindl E: Disease progression mediated by egr-1 associated signaling in response to oxidative stress. Int J Mol Sci. 13:13104–13117. 2012. View Article : Google Scholar : PubMed/NCBI
16	Gitenay D and Baron VT: Is EGR1 a potential target for prostate cancer therapy? Future Oncol. 5:993–1003. 2009. View Article : Google Scholar : PubMed/NCBI
17	Walia G, Pienta KJ, Simons JW and Soule HR: The 19th annual Prostate Cancer Foundation scientific retreat. Cancer Res. 73:4988–4991. 2013. View Article : Google Scholar : PubMed/NCBI
18	Delongchamps NB and Haas GP: Saturation biopsies for prostate cancer: Current uses and future prospects. Nat Rev Urol. 6:645–652. 2009. View Article : Google Scholar : PubMed/NCBI
19	Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM and Kleijnen J: Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review. J Urol. 175:1605–1612. 2006. View Article : Google Scholar : PubMed/NCBI
20	Presti JC Jr: Prostate biopsy strategies. Nat Clin Pract Urol. 4:505–511. 2007. View Article : Google Scholar : PubMed/NCBI
21	Rabbani F, Stroumbakis N, Kava BR, Cookson MS and Fair WR: Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 159:1247–1250. 1998. View Article : Google Scholar : PubMed/NCBI
22	Patel AR and Jones JS: Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol. 19:232–237. 2009. View Article : Google Scholar : PubMed/NCBI
23	Pomerantz M: Active surveillance: Pathologic and clinical variables associated with outcome. Surg Pathol Clin. 8:581–585. 2015. View Article : Google Scholar : PubMed/NCBI
24	Mazzucchelli R, Galosi AB, Santoni M, Lopez-Beltran A, Scarpelli M, Cheng L and Montironi R: Role of the pathologist in active surveillance for prostate cancer. Anal Quant Cytopathol Histpathol. 37:65–68. 2015.PubMed/NCBI
25	Bellardita L, Valdagni R, van den Bergh R, Randsdorp H, Repetto C, Venderbos LD, Lane JA and Korfage IJ: How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol. 67:637–645. 2015. View Article : Google Scholar
26	Kwon O and Hong S: Active surveillance and surgery in localized prostate cancer. Minerva Urol Nefrol. 66:175–187. 2014.PubMed/NCBI
27	Lou DY and Fong L: Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. Urol Oncol. 34:182–192. 2016. View Article : Google Scholar
28	Lindner U, Lawrentschuk N, Schatloff O, Trachtenberg J and Lindner A: Evolution from active surveillance to focal therapy in the management of prostate cancer. Future Oncol. 7:775–787. 2011. View Article : Google Scholar : PubMed/NCBI
29	Marshall S and Taneja S: Focal therapy for prostate cancer: The current status. Prostate Int. 3:35–41. 2015. View Article : Google Scholar : PubMed/NCBI
30	Andreoiu M and Cheng L: Multifocal prostate cancer: Biologic, prognostic, and therapeutic implications. Hum Pathol. 41:781–793. 2010. View Article : Google Scholar : PubMed/NCBI
31	Pagel JI and Deindl E: Early growth response 1 - a transcription factor in the crossfire of signal transduction cascades. Indian J Biochem Biophys. 48:226–235. 2011.PubMed/NCBI
32	Adamson E, de Belle I, Mittal S, Wang Y, Hayakawa J, Korkmaz K, O'Hagan D, McClelland M and Mercola D: Egr1 signaling in prostate cancer. Cancer Biol Ther. 2:617–622. 2003. View Article : Google Scholar : PubMed/NCBI
33	Adamson ED and Mercola D: Egr1 transcription factor: Multiple roles in prostate tumor cell growth and survival. Tumour Biol. 23:93–102. 2002. View Article : Google Scholar : PubMed/NCBI
34	Heldin CH: Autocrine PDGF stimulation in malignancies. Ups J Med Sci. 117:83–91. 2012. View Article : Google Scholar : PubMed/NCBI
35	Heldin CH: Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 11:972013. View Article : Google Scholar : PubMed/NCBI
36	Baron A, Migita T, Tang D and Loda M: Fatty acid synthase: A metabolic oncogene in prostate cancer? J Cell Biochem. 91:47–53. 2004. View Article : Google Scholar
37	Zadra G, Photopoulos C and Loda M: The fat side of prostate cancer. Biochim Biophys Acta. 1831.1518–1532. 2013.
38	Husaini Y, Qiu MR, Lockwood GP, Luo XW, Shang P, Kuffner T, Tsai VW, Jiang L, Russell PJ, Brown DA, et al: Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice. PLoS One. 7:e438332012. View Article : Google Scholar : PubMed/NCBI
39	Vaňhara P, Hampl A, Kozubík A and Souček K: Growth/differentiation factor-15: Prostate cancer suppressor or promoter? Prostate Cancer Prostatic Dis. 15:320–328. 2012. View Article : Google Scholar
40	Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, et al: MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA. 94:11514–11519. 1997. View Article : Google Scholar : PubMed/NCBI
41	Karan D, Holzbeierlein J and Thrasher JB: Macrophage inhibitory cytokine-1: Possible bridge molecule of inflammation and prostate cancer. Cancer Res. 69:2–5. 2009. View Article : Google Scholar : PubMed/NCBI
42	Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA and Milbrandt J: EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem. 275:38524–38531. 2000. View Article : Google Scholar : PubMed/NCBI
43	Shim M and Eling TE: Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem. 280:18636–18642. 2005. View Article : Google Scholar : PubMed/NCBI
44	Mora GR, Olivier KR, Mitchell RF Jr, Jenkins RB and Tindall DJ: Regulation of expression of the early growth response gene-1 (EGR-1) in malignant and benign cells of the prostate. Prostate. 63:198–207. 2005. View Article : Google Scholar